In this article, Andrew Butcher writes about the importance of stakeholder engagement as effective but high-cost new therapies have potentially damaging financial implications for the healthcare systems expected to fund them. Regrettably, the pharmaceutical industry is often identified as the cause of the problems rather than the key players in solving them.
Access solutions: Reconciling potential for improved patient access with implementation realities
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...